MIBG for Refractory Neuroblastoma and Pheochromocytoma
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a best available therapy/compassionate use single institution study designed to
determine the palliative benefit and toxicity of 131I-MIBG in patients with progressive
neuroblastoma and metastatic pheochromocytoma who are not eligible for therapies of higher
priority. Patients may receive a range of doses depending on stem cell availability and tumor
involvement of bone marrow. Response rate, toxicity, and time to progression and death will
be evaluated.